About: Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on August 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована в серпні 2008 (uk) مقالة علمية نشرت في أغسطس 2008 (ar) scientific article published on August 2008 (en)
publication date	wds:Q37126131-6BD87F72-3D62-4ED0-B81C-494644207D22
publication date	2008-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37126131-885190F6-0BE6-41C4-8178-37BC022394B6
language of work or name	English
cites work	wds:Q37126131-1125F296-39BD-439B-A8AB-FA926197BBD9 wds:Q37126131-171D1C0A-EB3B-49AD-B4AD-6A7F393365BC wds:Q37126131-1982085D-94C0-41DB-B252-BF95EDD85E47 wds:Q37126131-2D93C1D9-E96C-4696-8EB8-27AC44C4D02C wds:Q37126131-31B74891-FF3B-491B-B38A-84D32F704352 wds:Q37126131-34A581A0-CCA7-43B2-B2E7-7A3627C648E6 wds:Q37126131-657964A3-6993-44B4-BE7E-B3EED1CACBEF wds:Q37126131-6922B29D-2D81-45DB-AC31-677C66B32B1F wds:Q37126131-6ABCE0FD-8739-49DD-B78E-593A2ED8F020 wds:Q37126131-6ACBCBD3-20E9-4E71-A52D-AD4E4D1C72B9 wds:Q37126131-72190076-162E-409F-A141-E003B808464B wds:Q37126131-7C945B23-A279-46BA-B1CD-B18B51D3E6A5 wds:Q37126131-82C68C6E-2A7B-46F0-BACF-1FA7F9C89214 wds:Q37126131-88D47520-E36C-4327-9C49-F21E64915CE1 wds:Q37126131-A49E4B13-E22B-4C3C-9D56-44270DE3D2A1 wds:Q37126131-D24DDA6A-A63A-42B2-975B-7C6245C2E6C0 wds:Q37126131-E0B56B00-9087-415D-AE70-3B170121F31C wds:Q37126131-E85E2444-616E-4F97-BDA1-EF2B59819A18 wds:Q37126131-F4850CFA-8FFF-4985-A7B7-E00D53C969EB
cites work	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer Reporting results of cancer treatment Systematic reviews in health care: Assessing the quality of controlled clinical trials New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Sorafenib in advanced clear-cell renal-cell carcinoma Phase II study of sorafenib in patients with advanced hepatocellular carcinoma Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. End points and United States Food and Drug Administration approval of oncology drugs Lapatinib plus capecitabine for HER2-positive advanced breast cancer Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer Measures of response: RECIST, WHO, and new alternatives Sensitivity analysis of progression-free survival with dependent withdrawal. Proposal for the use of progression-free survival in unblinded randomized trials Inference in randomized studies with informative censoring and discrete time-to-event endpoints
author name string	wds:Q37126131-05DB732E-26DF-4A1F-A8CB-2FF3CAA56244 wds:Q37126131-0C7B6D52-EE54-4F01-A259-28C9A4265013 wds:Q37126131-330C55C3-5DB9-4658-9EE6-18D38251E5DF wds:Q37126131-429777D2-E89A-43DA-9D21-58DFDC53C73F wds:Q37126131-F258CFA5-362A-4D12-BB89-15E059596642 wds:Q37126131-F3997E55-CCFF-4E30-A78C-D24D3F94B049
author name string	Lori E Dodd Edward L Korn Janet Dancey C Carl Jaffe Margaret M Mooney Lawrence V Rubinstein
rdfs:label	Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (en) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (nl) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (ast)
skos:prefLabel	Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (en) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (nl) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (ast)
name	Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (en) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (nl) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (ast)
author	wds:Q37126131-12572268-C9D6-406A-A886-5A6EBCDA66D2
author	Boris Freidlin
title	wds:Q37126131-6F2061F3-D682-44E7-BC14-1757455E3835
title	Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? (en)
page(s)	wds:Q37126131-69AD9919-945E-4931-BFE4-C43968F3148A
page(s)	3791-3796
instance of	wds:Q37126131-08e61348-35c0-4517-bfd2-c576d22209ad wds:Q37126131-1431115D-01A7-42DC-B2C9-5D5874D4A4C1
instance of	review article scholarly article
main subject	wds:Q37126131-045FD414-C8EC-4578-9181-C9954C556869
main subject	phase III clinical trial
PubMed ID	wds:Q37126131-E4455D11-E5E1-44EE-B405-2139FC913452
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18669467
PubMed ID	18669467
published in	wds:Q37126131-C66ED67A-9F0B-49C4-A16A-784383F1FF46
published in	Journal of Clinical Oncology
issue	wds:Q37126131-FBCB8BF5-19F4-4391-A612-5E50E5CBEAEC
volume	wds:Q37126131-829CAE57-4EE8-4077-94BA-922AB2DF4230
issue	22

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software